{"id":"NCT00789698","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia","officialTitle":"A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2008-11-13","resultsPosted":"2012-08-21","lastUpdate":"2015-06-12"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Schizophrenia"],"interventions":[{"type":"DRUG","name":"Lurasidone HC1","otherNames":[]},{"type":"DRUG","name":"Quetiapine XR","otherNames":[]}],"arms":[{"label":"Lurasidone HC1","type":"EXPERIMENTAL"},{"label":"Quetiapine","type":"ACTIVE_COMPARATOR"}],"summary":"Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.","primaryOutcome":{"measure":"Relapse of Psychotic Symptoms","timeFrame":"12 Months","effectByArm":[{"arm":"Lurasidone-Lurasidone","deltaMin":29,"sd":null},{"arm":"Quetiapine-Quetiapine","deltaMin":21,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":65,"countries":["United States","Colombia","India","Romania","Russia","Ukraine"]},"refs":{"pmids":["23583011","24035633","26117157"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":72},"commonTop":["Akathisia","Headache","Insomnia","Schizophrenia","Parkinsonism"]}}